The Clinical Alliance for Research and Education – Infectious Diseases (CARE-ID) Marks Its First Month in Expanding the Science for Effective COVID-19 Treatments
Annandale, VA; September 1, 2020
Beginning in the months of July and August this year, CARE-ID committed its research experience and resources to the fight against COVID-19. In doing so, it not only continues its role in advancing medicines for a variety of infectious diseases, now it is a notable participant in expanding the science for effective COVID-19 treatments. The first step came in partnering with Lilly and Company (Lilly) to conduct a clinical research study, BLAZE-1, to evaluate the safety and effectiveness of LY-CoV555 (an antibody therapy) in patients with early mild to moderate COVID-19. The promise of this drug is to help newly diagnosed patients clear the SARS-CoV-2 virus faster. The second, very quick, step was continuing the longstanding collaboration in place with Pfizer. In this case it was to conduct clinical research to evaluate the safety and effectiveness of its SARS-CoV-2-RNA vaccine candidate against COVID-19. The promise of a vaccine against COVID-19 is nearly impossible to overestimate in today’s fight against this pandemic disease.